Eli Lilly and Company (NYSE:LLY) Stake Lessened by Investment Partners LTD.

Investment Partners LTD. cut its stake in Eli Lilly and Company (NYSE:LLY) by 1.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,549 shares of the company’s stock after selling 79 shares during the period. Eli Lilly and Company makes up approximately 1.9% of Investment Partners LTD.’s investment portfolio, making the stock its 13th biggest position. Investment Partners LTD.’s holdings in Eli Lilly and Company were worth $3,818,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in LLY. JGP Wealth Management LLC lifted its stake in Eli Lilly and Company by 0.9% during the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after purchasing an additional 16 shares during the last quarter. Walkner Condon Financial Advisors LLC lifted its stake in Eli Lilly and Company by 2.8% during the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after purchasing an additional 17 shares during the last quarter. Patton Albertson Miller Group LLC lifted its stake in Eli Lilly and Company by 2.8% during the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after purchasing an additional 17 shares during the last quarter. Valley Wealth Managers Inc. lifted its stake in Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares during the last quarter. Finally, Sandy Cove Advisors LLC lifted its stake in Eli Lilly and Company by 0.8% during the fourth quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock valued at $1,307,000 after purchasing an additional 17 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

LLY traded up $8.64 during trading on Friday, hitting $733.51. The stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The firm has a market cap of $696.95 billion, a PE ratio of 126.47, a P/E/G ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $380.77 and a 12 month high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a 50 day simple moving average of $761.79 and a 200-day simple moving average of $666.06.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.09 EPS. Analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Truist Financial restated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Morgan Stanley upped their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Finally, JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.